JP2018515130A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018515130A5 JP2018515130A5 JP2018505536A JP2018505536A JP2018515130A5 JP 2018515130 A5 JP2018515130 A5 JP 2018515130A5 JP 2018505536 A JP2018505536 A JP 2018505536A JP 2018505536 A JP2018505536 A JP 2018505536A JP 2018515130 A5 JP2018515130 A5 JP 2018515130A5
- Authority
- JP
- Japan
- Prior art keywords
- arenavirus
- use according
- virus
- tumor
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000712891 Arenavirus Species 0.000 claims description 68
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 12
- 210000004881 tumor cell Anatomy 0.000 claims description 9
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 229920002477 rna polymer Polymers 0.000 claims description 8
- 241000700605 Viruses Species 0.000 claims description 7
- 210000004443 dendritic cell Anatomy 0.000 claims description 6
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 claims description 5
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 241000712890 Junin mammarenavirus Species 0.000 claims description 3
- 241001244466 New world arenaviruses Species 0.000 claims description 3
- 241001244462 Old world arenaviruses Species 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000002865 immune cell Anatomy 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 230000003044 adaptive effect Effects 0.000 claims 2
- 230000000259 anti-tumor effect Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 102000003996 Interferon-beta Human genes 0.000 claims 1
- 108090000467 Interferon-beta Proteins 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 229960003130 interferon gamma Drugs 0.000 claims 1
- 229960001388 interferon-beta Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 241001295068 Allpahuayo mammarenavirus Species 0.000 description 2
- 241000190711 Amapari mammarenavirus Species 0.000 description 2
- 241001440626 Bear Canyon mammarenavirus Species 0.000 description 2
- 241000659008 Chapare mammarenavirus Species 0.000 description 2
- 241001244472 Cupixi mammarenavirus Species 0.000 description 2
- 241000190598 Flexal mammarenavirus Species 0.000 description 2
- 241000190708 Guanarito mammarenavirus Species 0.000 description 2
- 241000190594 Parana mammarenavirus Species 0.000 description 2
- 241000712910 Pichinde mammarenavirus Species 0.000 description 2
- 241000245926 Pirital mammarenavirus Species 0.000 description 2
- 241000192617 Sabia mammarenavirus Species 0.000 description 2
- 241000712908 Tacaribe mammarenavirus Species 0.000 description 2
- 241000190592 Tamiami mammarenavirus Species 0.000 description 2
- 241000205658 Whitewater Arroyo mammarenavirus Species 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- 206010061424 Anal cancer Diseases 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 206010008761 Choriomeningitis lymphocytic Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 241000555269 Ippy mammarenavirus Species 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 241000712902 Lassa mammarenavirus Species 0.000 description 1
- 241000190596 Latino mammarenavirus Species 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000712898 Machupo mammarenavirus Species 0.000 description 1
- 241000555271 Mobala mammarenavirus Species 0.000 description 1
- 241000712897 Mopeia mammarenavirus Species 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 241000146363 Oliveros mammarenavirus Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000001419 lymphocytic choriomeningitis Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 1
- 208000029974 neurofibrosarcoma Diseases 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021088871A JP7273102B2 (ja) | 2015-04-17 | 2021-05-27 | 腫瘍の治療および／または阻止において使用するためのアレナウイルス（ａｒｅｎａｖｉｒｕｓｅｓ）、および、（改善された）腫瘍退縮特性（ｔｕｍｏｒ－ｒｅｇｒｅｓｓｉｏｎ ｐｒｏｐｅｒｔｉｅｓ）を有するアレナウイルス（ａｒｅｎａｖｉｒｕｓｅｓ）を産生するための方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102015207036.0 | 2015-04-17 | ||
| DE102015207036.0A DE102015207036A1 (de) | 2015-04-17 | 2015-04-17 | Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften |
| PCT/EP2016/058347 WO2016166285A1 (de) | 2015-04-17 | 2016-04-15 | Arenaviren zur anwendung bei der behandlung und/oder vorbeugung von tumoren sowie verfahren zur herstellung von arenaviren mit (verbesserten) tumorregressiven eigenschaften |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021088871A Division JP7273102B2 (ja) | 2015-04-17 | 2021-05-27 | 腫瘍の治療および／または阻止において使用するためのアレナウイルス（ａｒｅｎａｖｉｒｕｓｅｓ）、および、（改善された）腫瘍退縮特性（ｔｕｍｏｒ－ｒｅｇｒｅｓｓｉｏｎ ｐｒｏｐｅｒｔｉｅｓ）を有するアレナウイルス（ａｒｅｎａｖｉｒｕｓｅｓ）を産生するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018515130A JP2018515130A (ja) | 2018-06-14 |
| JP2018515130A5 true JP2018515130A5 (enExample) | 2019-05-23 |
| JP7039037B2 JP7039037B2 (ja) | 2022-03-22 |
Family
ID=55759589
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018505536A Active JP7039037B2 (ja) | 2015-04-17 | 2016-04-15 | 腫瘍の治療および／または阻止において使用するためのアレナウイルス（ａｒｅｎａｖｉｒｕｓｅｓ）、および、（改善された）腫瘍退縮特性（ｔｕｍｏｒ－ｒｅｇｒｅｓｓｉｏｎ ｐｒｏｐｅｒｔｉｅｓ）を有するアレナウイルス（ａｒｅｎａｖｉｒｕｓｅｓ）を産生するための方法 |
| JP2021088871A Active JP7273102B2 (ja) | 2015-04-17 | 2021-05-27 | 腫瘍の治療および／または阻止において使用するためのアレナウイルス（ａｒｅｎａｖｉｒｕｓｅｓ）、および、（改善された）腫瘍退縮特性（ｔｕｍｏｒ－ｒｅｇｒｅｓｓｉｏｎ ｐｒｏｐｅｒｔｉｅｓ）を有するアレナウイルス（ａｒｅｎａｖｉｒｕｓｅｓ）を産生するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021088871A Active JP7273102B2 (ja) | 2015-04-17 | 2021-05-27 | 腫瘍の治療および／または阻止において使用するためのアレナウイルス（ａｒｅｎａｖｉｒｕｓｅｓ）、および、（改善された）腫瘍退縮特性（ｔｕｍｏｒ－ｒｅｇｒｅｓｓｉｏｎ ｐｒｏｐｅｒｔｉｅｓ）を有するアレナウイルス（ａｒｅｎａｖｉｒｕｓｅｓ）を産生するための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20180117137A1 (enExample) |
| EP (1) | EP3283104B1 (enExample) |
| JP (2) | JP7039037B2 (enExample) |
| CN (1) | CN108025054B (enExample) |
| CA (1) | CA2982873A1 (enExample) |
| DE (1) | DE102015207036A1 (enExample) |
| ES (1) | ES3017684T3 (enExample) |
| WO (1) | WO2016166285A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3218504B1 (en) | 2014-11-13 | 2020-07-22 | Université de Genève | Tri-segmented arenaviruses as vaccine vectors |
| DE102015207036A1 (de) | 2015-04-17 | 2016-10-20 | Karl Sebastian Lang | Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften |
| CA2987155A1 (en) | 2015-06-10 | 2016-12-15 | Hookipa Biotech Ag | Hpv vaccines |
| CA3003557A1 (en) | 2015-11-04 | 2017-05-11 | Hookipa Biotech Ag | Vaccines against hepatitis b virus |
| US11266727B2 (en) | 2015-11-12 | 2022-03-08 | Hookipa Biotech Gmbh | Arenavirus particles as cancer vaccines |
| EP3606549A1 (en) * | 2017-04-07 | 2020-02-12 | Hookipa Biotech GmbH | Arenavirus particles to treat solid tumors |
| DE102018215551A1 (de) * | 2018-09-12 | 2020-03-12 | Virolutions Biotech Gmbh | Verfahren zur Herstellung eines antitumoralen Arenavirus sowie Arenavirusmutanten |
| WO2022180203A1 (en) | 2021-02-26 | 2022-09-01 | Abalos Therapeutics Gmbh | New virus particles for therapeutic purposes |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004034461B4 (de) | 2004-07-16 | 2008-02-07 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Gentherapie solider Tumore durch retrovirale, mit Arenavirus-Glykoprotein pseudotypisierte Vektoren |
| US7994221B2 (en) | 2004-12-06 | 2011-08-09 | Siga Technologies, Inc. | Sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses |
| CN103255169A (zh) | 2007-12-27 | 2013-08-21 | 苏黎士大学 | 复制缺陷型沙粒病毒载体 |
| WO2011056993A1 (en) * | 2009-11-04 | 2011-05-12 | Yale University | Compositions and methods for treating cancer with attenuated oncolytic viruses |
| DE102015207036A1 (de) | 2015-04-17 | 2016-10-20 | Karl Sebastian Lang | Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften |
-
2015
- 2015-04-17 DE DE102015207036.0A patent/DE102015207036A1/de active Pending
-
2016
- 2016-04-15 JP JP2018505536A patent/JP7039037B2/ja active Active
- 2016-04-15 CN CN201680030624.5A patent/CN108025054B/zh active Active
- 2016-04-15 WO PCT/EP2016/058347 patent/WO2016166285A1/de not_active Ceased
- 2016-04-15 EP EP16717129.7A patent/EP3283104B1/de active Active
- 2016-04-15 US US15/567,343 patent/US20180117137A1/en not_active Abandoned
- 2016-04-15 CA CA2982873A patent/CA2982873A1/en active Pending
- 2016-04-15 ES ES16717129T patent/ES3017684T3/es active Active
-
2019
- 2019-02-04 US US16/267,095 patent/US11801294B2/en active Active
-
2021
- 2021-05-27 JP JP2021088871A patent/JP7273102B2/ja active Active
-
2023
- 2023-10-30 US US18/385,250 patent/US12409217B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018515130A5 (enExample) | ||
| JP7273102B2 (ja) | 腫瘍の治療および／または阻止において使用するためのアレナウイルス（ａｒｅｎａｖｉｒｕｓｅｓ）、および、（改善された）腫瘍退縮特性（ｔｕｍｏｒ－ｒｅｇｒｅｓｓｉｏｎ ｐｒｏｐｅｒｔｉｅｓ）を有するアレナウイルス（ａｒｅｎａｖｉｒｕｓｅｓ）を産生するための方法 | |
| Wang et al. | Virus-induced hepatocellular carcinoma with special emphasis on HBV | |
| Yoo et al. | Oncolytic virus‐based immunotherapies for hepatocellular carcinoma | |
| CN118853594A (zh) | 嵌合痘病毒组合物及其用途 | |
| JP2020503010A5 (enExample) | ||
| JP2013538790A5 (enExample) | ||
| JP2014534269A5 (enExample) | ||
| JP2018532736A5 (enExample) | ||
| RU2012110580A (ru) | Способы скрининга in vivo | |
| JP2018522041A5 (enExample) | ||
| Wang et al. | Co-circulation of hantaan, kenkeme, and khabarovsk hantaviruses in Bolshoy Ussuriysky island, China | |
| JP2023096009A5 (enExample) | ||
| JP2016533373A5 (enExample) | ||
| Price et al. | Evolution of malignant glioma treatment: from chemotherapy to vaccines to viruses | |
| Zhang et al. | Epigenetic modification of hepatitis B virus infection and related hepatocellular carcinoma | |
| Jindra et al. | Influenza virus vector iNS1 expressing bovine papillomavirus 1 (BPV1) antigens efficiently induces tumour regression in equine sarcoid patients | |
| Kamath et al. | Therapeutic potential of combating cancer by restoring wild-type p53 through mRNA nanodelivery | |
| CN115998883B (zh) | Cflar的抑制剂在治疗arid1a缺失型肿瘤中的应用 | |
| Sultan et al. | Precision oncolytic viral therapy in colorectal cancer: Genetic targeting and immune modulation for personalized treatment | |
| WO2019164451A8 (en) | Cancer therapeutic targeting using mutant p53-specific sirnas | |
| JP2020500907A5 (enExample) | ||
| JP2016505009A5 (enExample) | ||
| JP2016506722A5 (enExample) | ||
| US20240318147A1 (en) | Recombinant oncolytic virus, and construction method therefor and use thereof |